GMDAQ vs. WINT, ELOX, ALBT, FNCH, KRBP, TCBP, SCNI, SQZ, TCON, and FRTX
Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), SQZ Biotechnologies (SQZ), TRACON Pharmaceuticals (TCON), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDAQ) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
Windtree Therapeutics received 3 more outperform votes than Gamida Cell when rated by MarketBeat users.
Gamida Cell's return on equity of 0.00% beat Windtree Therapeutics' return on equity.
In the previous week, Gamida Cell had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 1 mentions for Gamida Cell and 0 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.98 beat Gamida Cell's score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the news media.
Gamida Cell has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
50.3% of Gamida Cell shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 6.7% of Gamida Cell shares are owned by insiders. Comparatively, 0.5% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Windtree Therapeutics has lower revenue, but higher earnings than Gamida Cell. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Summary
Gamida Cell beats Windtree Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Gamida Cell News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMDAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMDAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GMDAQ vs. The Competition
Gamida Cell Competitors List
Related Companies and Tools
